American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies

Regis J. O'Keefe, Rocky S. Tuan, Nancy E. Lane, Frank Barry, Bruce A. Bunnell, Céline Colnot, Matthew T. Drake, Hicham Drissi, Lisa A. Fortier, Robert E. Guldberg, David G. Little, Mary F. Marshall, Jeremy J. Mao, Norimasa Nakamura, Pamela G. Robey, Vicki Rosen, David W. Rowe, Edward M. Schwarz

Research output: Contribution to journalArticle

Abstract

Cell-based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell-based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web-based marketing and patient testimonials supporting cell-based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell-based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell-based therapies. The Task Force was charged with defining the state-of-the art in cell-based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell-based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration.

Original languageEnglish (US)
JournalJournal of Bone and Mineral Research
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Advisory Committees
Cell- and Tissue-Based Therapy
Joints
Research
Musculoskeletal System
Bone Regeneration
Marketing
Research Personnel
Tissue Donors
Organizations
Physicians
Therapeutics
Population

Keywords

  • ANIMAL MODELS
  • CELL/TISSUE SIGNALING, TRANSCRIPTION FACTORS
  • CELLS OF BONE
  • CLINICAL TRIALS
  • GENETIC RESEARCH

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies. / O'Keefe, Regis J.; Tuan, Rocky S.; Lane, Nancy E.; Barry, Frank; Bunnell, Bruce A.; Colnot, Céline; Drake, Matthew T.; Drissi, Hicham; Fortier, Lisa A.; Guldberg, Robert E.; Little, David G.; Marshall, Mary F.; Mao, Jeremy J.; Nakamura, Norimasa; Robey, Pamela G.; Rosen, Vicki; Rowe, David W.; Schwarz, Edward M.

In: Journal of Bone and Mineral Research, 01.01.2019.

Research output: Contribution to journalArticle

O'Keefe, RJ, Tuan, RS, Lane, NE, Barry, F, Bunnell, BA, Colnot, C, Drake, MT, Drissi, H, Fortier, LA, Guldberg, RE, Little, DG, Marshall, MF, Mao, JJ, Nakamura, N, Robey, PG, Rosen, V, Rowe, DW & Schwarz, EM 2019, 'American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies', Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.3839
O'Keefe, Regis J. ; Tuan, Rocky S. ; Lane, Nancy E. ; Barry, Frank ; Bunnell, Bruce A. ; Colnot, Céline ; Drake, Matthew T. ; Drissi, Hicham ; Fortier, Lisa A. ; Guldberg, Robert E. ; Little, David G. ; Marshall, Mary F. ; Mao, Jeremy J. ; Nakamura, Norimasa ; Robey, Pamela G. ; Rosen, Vicki ; Rowe, David W. ; Schwarz, Edward M. / American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies. In: Journal of Bone and Mineral Research. 2019.
@article{9cbff712e64d423fb2a75166ded6a7b1,
title = "American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies",
abstract = "Cell-based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell-based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web-based marketing and patient testimonials supporting cell-based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell-based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell-based therapies. The Task Force was charged with defining the state-of-the art in cell-based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell-based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration.",
keywords = "ANIMAL MODELS, CELL/TISSUE SIGNALING, TRANSCRIPTION FACTORS, CELLS OF BONE, CLINICAL TRIALS, GENETIC RESEARCH",
author = "O'Keefe, {Regis J.} and Tuan, {Rocky S.} and Lane, {Nancy E.} and Frank Barry and Bunnell, {Bruce A.} and C{\'e}line Colnot and Drake, {Matthew T.} and Hicham Drissi and Fortier, {Lisa A.} and Guldberg, {Robert E.} and Little, {David G.} and Marshall, {Mary F.} and Mao, {Jeremy J.} and Norimasa Nakamura and Robey, {Pamela G.} and Vicki Rosen and Rowe, {David W.} and Schwarz, {Edward M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jbmr.3839",
language = "English (US)",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies

AU - O'Keefe, Regis J.

AU - Tuan, Rocky S.

AU - Lane, Nancy E.

AU - Barry, Frank

AU - Bunnell, Bruce A.

AU - Colnot, Céline

AU - Drake, Matthew T.

AU - Drissi, Hicham

AU - Fortier, Lisa A.

AU - Guldberg, Robert E.

AU - Little, David G.

AU - Marshall, Mary F.

AU - Mao, Jeremy J.

AU - Nakamura, Norimasa

AU - Robey, Pamela G.

AU - Rosen, Vicki

AU - Rowe, David W.

AU - Schwarz, Edward M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cell-based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell-based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web-based marketing and patient testimonials supporting cell-based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell-based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell-based therapies. The Task Force was charged with defining the state-of-the art in cell-based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell-based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration.

AB - Cell-based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell-based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web-based marketing and patient testimonials supporting cell-based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell-based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell-based therapies. The Task Force was charged with defining the state-of-the art in cell-based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell-based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration.

KW - ANIMAL MODELS

KW - CELL/TISSUE SIGNALING, TRANSCRIPTION FACTORS

KW - CELLS OF BONE

KW - CLINICAL TRIALS

KW - GENETIC RESEARCH

UR - http://www.scopus.com/inward/record.url?scp=85073942208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073942208&partnerID=8YFLogxK

U2 - 10.1002/jbmr.3839

DO - 10.1002/jbmr.3839

M3 - Article

C2 - 31545883

AN - SCOPUS:85073942208

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

ER -